Juncture Wealth Strategies’s Catalyst Pharmaceutical CPRX Stock Holding History

Juncture Wealth Strategies’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$579K	Sell	18,408 -53,401	-74%	-$1.58M	0.15%	102
2026 Q1	$1.78M	Sell	71,809 -12,533	-15%	-$299K	0.59%	33
2025 Q4	$1.97M	Buy	84,342 +940	+1%	+$20.9K	0.65%	29
2025 Q3	$1.64M	Sell	83,402 -7,897	-9%	-$162K	0.55%	35
2025 Q2	$1.98M	Sell	91,299 -4,825	-5%	-$114K	0.7%	27
2025 Q1	$2.33M	Sell	96,124 -1,273	-1%	-$28.7K	0.91%	20
2024 Q4	$2.03M	Buy	97,397 +160	+0.2%	+$3.44K	0.76%	23
2024 Q3	$1.93M	Buy	97,237 +436	+0.5%	+$8.08K	0.75%	22
2024 Q2	$1.5M	Buy	96,801 +2,218	+2%	+$34.5K	0.63%	28
2024 Q1	$1.51M	Buy	94,583 +83,636	+764%	+$1.26M	0.65%	28
2023 Q4	$184K	Sell	10,947 -140	-1%	-$1.91K	0.08%	104
2023 Q3	$130K	Sell	11,087 -28,387	-72%	-$380K	0.06%	113
2023 Q2	$531K	Sell	39,474 -908	-2%	-$13.1K	0.25%	81
2023 Q1	$670K	Buy	+40,382	New	+$666K	0.33%	58

Other funds holding CPRX

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

LTAS

Linden Thomas Advisory Services Charlotte, North Carolina $1.24B AUM 47.37% 1-Year Est. Return

COPPSERS

Commonwealth of Pennsylvania Public School Employees Retirement System Harrisburg, Pennsylvania $20.6B AUM 37.37% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

RFG Advisory Birmingham, Alabama $6.4B AUM 19.93% 1-Year Est. Return

YIH

Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return

EWM

Empirical Wealth Management Seattle, Washington $6.85B AUM 30.02% 1-Year Est. Return

OLA

Oliver Luxxe Assets Gladstone, New Jersey $680M AUM 47.51% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

Juncture Wealth Strategies's CPRX Position: Q2 2026 in Review

Juncture Wealth Strategies reduced its Catalyst Pharmaceutical (CPRX) stake by 74% in Q2 2026, selling an estimated $1.58M and leaving 18,408 shares worth $579K. The position accounts for 0.15% of the portfolio, ranked #102.

Juncture Wealth Strategies first reported a position in CPRX in Q1 2023 and has held it in 14 quarters since. The position peaked at $2.33M in Q1 2025. 36 funds tracked by Wall St. Rank hold CPRX as of Q2 2026.

Juncture Wealth Strategies held 18,408 shares of Catalyst Pharmaceutical worth $579K as of Q2 2026.
Juncture Wealth Strategies sold 53,401 Catalyst Pharmaceutical shares in Q2 2026, an estimated $1.58M.
Catalyst Pharmaceutical made up 0.15% of Juncture Wealth Strategies's portfolio in Q2 2026, its #102 holding.
Juncture Wealth Strategies first reported a position in Catalyst Pharmaceutical in Q1 2023 and has held it in 14 quarters since.
Juncture Wealth Strategies's Catalyst Pharmaceutical position peaked at $2.33M in Q1 2025.
36 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2026.

Based on Juncture Wealth Strategies's 13F filing for Q2 2026, filed 9 Jul 2026.